Trials / Completed
CompletedNCT04530838
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY UNBLIND TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF A 20-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY JAPANESE INFANTS
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 668 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 2 Months – 6 Months
- Healthy volunteers
- Accepted
Summary
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | 20-valent pneumococcal conjugate vaccine | 20-valent pneumococcal conjugate vaccine |
| BIOLOGICAL | 13-valent pneumococcal conjugate vaccine | 13-valent pneumococcal conjugate vaccine |
Timeline
- Start date
- 2020-09-16
- Primary completion
- 2022-04-02
- Completion
- 2022-04-02
- First posted
- 2020-08-28
- Last updated
- 2023-04-21
- Results posted
- 2023-04-21
Locations
38 sites across 1 country: Japan
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04530838. Inclusion in this directory is not an endorsement.